How big is Cumberland Pharmaceuticals, Inc.?

As of Jun 18, Cumberland Pharmaceuticals, Inc. has a market capitalization of 80.79 million and reported net sales of 41.09 million with a net profit of -3.29 million over the latest four quarters. Shareholder's funds are 22.85 million, and total assets amount to 75.58 million.

As of Jun 18, Cumberland Pharmaceuticals, Inc. has a market capitalization of 80.79 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 41.09 million for the latest four quarters. During the same period, Cumberland Pharmaceuticals, Inc. experienced a net profit of -3.29 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 22.85 million and total assets amounting to 75.58 million.

What does Cumberland Pharmaceuticals, Inc. do?

Cumberland Pharmaceuticals, Inc. is a micro-cap specialty pharmaceutical company focused on developing and commercializing branded prescription products. As of March 2025, it reported net sales of $12 million and a net profit of $1 million, with a market cap of $80.79 million.

Overview:<BR>Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription products within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 12 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 1 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 80.79 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.33<BR>- Return on Equity: -12.87%<BR>- Price to Book: 2.82<BR><BR>Contact Details:<BR>- Address: 2525 W End Ave Ste 950, NASHVILLE TN: 37203-1608<BR>- Tel: 1 615 2550068<BR>- Fax: 1 615 2550094<BR>- Website: http://www.cumberlandpharma.com/

Should I buy, sell or hold Cumberland Pharmaceuticals, Inc.?

Who are in the management team of Cumberland Pharmaceuticals, Inc.?

As of March 2022, the management team of Cumberland Pharmaceuticals, Inc. includes A. Kazimi (Chairman and CEO), Martin Cearnal (Executive VP and Chief Commercial Officer), and several independent directors: Gordon Bernard, Joseph Galante, Jonathan Griggs, Joey Jacobs, and James Jones. This team provides executive leadership and governance for the company.

As of March 2022, the management team of Cumberland Pharmaceuticals, Inc. includes:<BR><BR>- Mr. A. Kazimi, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Martin Cearnal, who is the Executive Vice President, Chief Commercial Officer, and a Director.<BR>- Dr. Gordon Bernard, who is an Independent Director.<BR>- Mr. Joseph Galante, who is also an Independent Director.<BR>- Mr. Jonathan Griggs, who serves as an Independent Director.<BR>- Mr. Joey Jacobs, who is an Independent Director.<BR>- Mr. James Jones, who is another Independent Director. <BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Cumberland Pharmaceuticals, Inc. overvalued or undervalued?

Cumberland Pharmaceuticals, Inc. is considered overvalued due to high valuation ratios, such as a Price to Book Value of 3.04 and an EV to EBITDA of 34.34, alongside a negative ROCE of -19.13% and poor long-term returns, despite a recent impressive one-year return of 164.80%.

As of 2 August 2016, the valuation grade for Cumberland Pharmaceuticals, Inc. moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 3.04 and an EV to EBITDA ratio of 34.34, which suggests a high valuation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the ROCE stands at -19.13%, reflecting significant inefficiencies in generating returns on capital employed.<BR><BR>In comparison to its peers, Cumberland's valuation ratios are concerning; for instance, Regulus Therapeutics, Inc. has a lower EV to EBITDA of -9.1364, indicating a more favorable valuation relative to earnings. Furthermore, while Cumberland has shown impressive returns over the past year at 164.80%, this is contrasted by a lackluster 5-year return of -0.60%, suggesting volatility and potential overvaluation in the long term. Overall, the combination of high valuation ratios and poor return metrics leads to the conclusion that Cumberland Pharmaceuticals, Inc. is overvalued.

Is Cumberland Pharmaceuticals, Inc. technically bullish or bearish?

As of August 20, 2025, Cumberland Pharmaceuticals, Inc. exhibits a mildly bearish technical trend, with mixed signals across time frames, despite having outperformed the S&P 500 over the past year.

As of 20 August 2025, the technical trend for Cumberland Pharmaceuticals, Inc. has changed from mildly bullish to mildly bearish. The weekly MACD and KST are both bearish, while the monthly MACD and KST are bullish, indicating mixed signals across time frames. The daily moving averages are bearish, and the weekly Bollinger Bands are also bearish, contributing to the overall bearish stance. The Dow Theory shows a mildly bearish trend on the weekly chart with no trend on the monthly chart. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past year with a return of 164.80% compared to the S&P 500's 17.14%, but it has underperformed over the last 3 years and 5 years. Overall, the current technical stance is mildly bearish, reflecting short-term weakness despite strong long-term performance.